Abstract: Disclosed is related to a printing device for performing a multi-color gravure offset printing operation in one rotation of a gravure offset roll for various shapes of printing material, and a method therefor. The printing device includes at least: a blanket roll having a cylindrical shape and moving in a first direction while rotating; an ink transfer unit including one or more ink transfer plates which is in contact with a lower end of the blanket roll; a squeeze unit moving in a second direction in a state in which one end thereof comes in contact with the ink transfer plate, wherein the second direction forms a predetermined angle with respect to the first direction or is orthogonal to the first direction. According to the present invention, an effect of enabling gravure offset printing in one printing cycle on various shapes of printing material is provided.

Abstract: Disclosed is related to a printing device for performing a multi-color gravure offset printing operation in one rotation of a gravure offset roll for various shapes of printing material, and a method therefor. The printing device includes at least: a blanket roll having a cylindrical shape and moving in a first direction while rotating; an ink transfer unit including one or more ink transfer plates which is in contact with a lower end of the blanket roll; a squeeze unit moving in a second direction in a state in which one end thereof comes in contact with the ink transfer plate, wherein the second direction forms a predetermined angle with respect to the first direction or is orthogonal to the first direction. According to the present invention, an effect of enabling gravure offset printing in one printing cycle on various shapes of printing material is provided.

Abstract: The invention is novel compounds of formula which exhibit an improved therapeutic index and improved metabolic stability which are useful in the treatment and/or prevention of herpes viral infections. Novel intermediates useful in the synthesis of the final compounds are also part of the invention.

Abstract: The invention is novel compounds of formula (I) which exhibit an improved therapeutic index and improved metabolic stability which are useful in the treatment and/or prevention of herpes viral infections. Novel intermediates useful in the synthesis of the final compounds are also part of the invention.

Abstract: Chroman derivatives of the formula ?I! ##STR1## wherein R.sup.1 is a cyano, a nitro, a trihalomethyl, a trihalomethoxy or a halogen atom; R.sup.2 is a lower alkoxyalkyl, an aryloxyalkyl or a dialkoxyalkyl; R.sup.3 is a lower alkoxyalkyl or an aryloxyalkyl; R.sup.4 is a hydroxy, a formyloxy or a lower alkanoyloxy; X is N--H, an N--optionally substituted lower alkyl, an oxygen atom, a sulfur atom or a single bond; and Y is an optionally substituted aromatic ring residue or an optionally substituted heterocyclic residue, pharmaceutically acceptable salts thereof and pharmaceutical use thereof. The compound of the present invention and pharmaceutically acceptable salts thereof have selective and excellent coronary vasodilating action and extremely weak hypotensive action.

Abstract: Disclosed herein are pyrroloazepine derivatives having anti-.alpha..sub.1 activity and anti-serotonin activity represented by the following formula (I): ##STR1## wherein R means a hydrogen atom, a linear or branched C.sub.1-6 alkyl group or a C.sub.7-10 aralkyl group, A denotes a linear or branched C.sub.2-10 alkylene, alkenylene or alkynylene group, Z stands for O, NOR.sub.1 or NOCOR.sub.5 in which R.sub.1 and R.sub.5 is a hydrogen atom or an alkyl, aryl or aralkyl group, and Y means a particular piperidinyl or pyrrolidinyl group; and salts thereof. Their preparation processes are also disclosed.

Abstract: This invention provides a pyrroloazepine derivative represented by the following formula (I): ##STR1## where the substituents are defined in the specification. The pyrroloazepine derivatives according to the present invention are drugs having excellent anti-.alpha..sub.1 action and anti-serotonin action and feature high safety. They can therefore be used, for example, as novel therapeutics for circulatory diseases.

Abstract: Disclosed herein are pyrroloazepine derivatives, which are useful as therapeutics for circulatory diseases, represented by the following formula (I): ##STR1## wherein R means a hydrogen atom, a linear or branched C.sub.1-6 alkyl group or a C.sub.7-10 aralkyl group, A denotes a linear or branched C.sub.2-10 alkylene, alkenylene or alkynylene group, Z stands for O, NOR.sub.1 or NOCOR.sub.5 in which R.sub.1 and R.sub.5 is a hydrogen atom or an alkyl, aryl or aralkyl group, and Y means a particular piperidinyl or pyrrolidinyl group; and salts thereof. Their preparation processes are also disclosed.

Abstract: Described are caffeic acid derivatives represented by the following formula: ##STR1## wherein either one of R.sup.1 and R.sup.2 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group, a group --CO.sub.2 R.sup.4, or a group --CONR.sup.5 R.sup.6, R.sup.4, R.sup.5 and R.sup.6 being either a hydrogen atom or a particular group, and the other is the group --CO.sub.2 R.sup.4 or the group --CONR.sup.5 R.sup.6, or R.sup.1 and R.sup.2 are coupled together to represent a 5-membered ring so formed, Y represents a particular group or atom, X represents a substituted or unsubstituted C.sub.6 -C.sub.10 aryl, C.sub.7 -C.sub.12 aralkyl, heterocyclic or heterocyclic ring-alkyl group, m and n stand for particular integers, and R.sup.3 represents a hydrogen atom, a hydroxyl group, a group --OCO.sub.2 R.sup.7, R.sup.7 being a hydrogen atom or a particular group, or a group --OCONR.sup.8 R.sup.9, R.sup.8 representing a C.sub.1 -C.sub.6 alkyl group and R.sup.9 representing a hydrogen atom or a C.sub.1 -C.sub.

Abstract: Described are caffeic acid derivatives represented by the following formula: ##STR1## wherein either one of R.sup.1 and R.sup.2 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group, a group --CO.sub.2 R.sup.4, or a group --CONR.sup.5 R.sup.6, R.sup.4, R.sup.5 and R.sup.6 being either a hydrogen atom or a particular group, and the other is the group --CO.sub.2 R.sub.4 or the group --CONF.sup.5 R.sup.6, or R.sup.1 and R.sup.2 are coupled together to represent a 5-membered ring so formed, Y represents a particular group or atom, X represents a substituted or unsubstituted C.sub.6 -C.sub.10 aryl, C.sub.7 -C.sub.12 aralkyl, heterocyclic or heterocyclic ring-alkyl group, m and n stand for particular integers, and R.sub.3 represents a hydrogen atom, a hydroxyl group, a group --OCO.sub.2 R.sup.7, R.sup.7 being a hydrogen atom or a particular group, or a group --OCONR.sup.8 R.sup.9, R.sup.8 representing a C.sub.1 -C.sub.6 alkyl group and R.sup.9 representing a hydrogen atom or a C.sub.1 -C.sub.

Abstract: Disclosed herein are pyrroloazepine derivatives, which are useful as therapeutics for circulatory diseases, represented by the following formula (I): ##STR1## wherein R means a hydrogen atom, a linear or branched C.sub.1-6 alkyl group or a C.sub.7-10 aralkyl group, A denotes a linear or branched C.sub.2-10 alkylene, alkenylene or alkynylene group, Z stands for O, NOR.sub.1 or NOCOR.sub.5 in which R.sub.1 and R.sub.5 is a hydrogen atom or an alkyl, aryl or aralkyl group, and Y means a particular piperidinyl or pyrrolidinyl group; and salts thereof. Their preparation processes are also disclosed.

Abstract: Novel derivatives of caffeic acid of the general formula (I): ##STR1## wherein X is hydrogen atom or hydroxy; R.sup.1 is hydrogen atom, a straight or branched alkyl or alkenyl having 1 to 20 carbon atoms or a group of the formula:--(CH.sub.2).sub.n --Z--R.sup.2wherein n is an integer of 1 to 10; Z is oxygen atom, vinylene residue or a single bond; and R.sup.2 is a substituted or unsubstituted phenyl or heterocyclic residue is provided. These derivatives possess 12-lipoxygenase inhibitory activity and are useful for curing and preventing circulatory diseases. A pharmaceutical composition containing said derivtive is also provided.

Abstract: N-substituted 3,4-dihydropyrimidine compounds of the formula: ##STR1## wherein R is straight, branched, cyclic or cyclo-straight alkyl having from one to four carbon atoms; and X.sup.1, X.sup.2 and X.sup.3 are the same or different and are hydrogen, halogen, lower alkyl having from one to four carbon atoms, lower alkoxy having from one to four carbon atoms, nitro, trifluoromethyl, hydroxy, or t-butyldimethylsilyloxy with the proviso that the case wherein X.sup.1, X.sup.2 and X.sup.3 are all hydrogen is not applicable have substantially strong and lasting vasodilative effects. Therefore, the compounds are useful as agents for treating disorders of the cardiovascular system, for example, antihypertensive agents, circulation improver and antianginal agents.

Abstract: 1,4-Dihydropyridine derivatives of the formula (1): ##STR1## wherein X is a halogen; R.sup.1 is a straight, branched or cyclic alkyl group having 1 to 10 carbon atoms, the group --(CH.sub.2).sub.n -Y [where n is an integer of 0 to 8, provided that n is an integer of 2 to 8 when Y is not bonded to COO-- through carbon; Y is a cyclic alkyl group having 3-6 carbon atoms, an aryl group having 6-10 carbon atoms, a pyrrolidinyl group, an imidazolidinyl group, a thienyl group, a furyl group, an imidazolyl group, a pyridyl group, a pyrimidinyl group, a morpholinyl group, a thiomorpholinyl group or a pyrrolizidinyl group, the group ##STR2## (where D is an aryl or aralkyl group having 6-15 carbon atoms which may be substituted by a halogenated alkyl group), or a 3-piperidinyl group substituted by a phenylalkyl group of 7-10 carbon atoms which may be substituted by one or two halogens], the group --(CH.sub.2).sub.

Abstract: A N-substituted 3,4-dihydropyrimidine derivative of the formula (1): ##STR1## Wherein R.sup.1 is --(CH.sub.2).sub.n --X; X is substituted aminoethyl, substituted sulfideethyl, substituted or nonsubstituted heterocyclo-ethyl wherein the ethylene group is directly bonded to a hetero atom in the heterocyclic ring, or substituted or nonsubstituted heterocyclo-methyl wherein the methylene group is directly bonded to a carbon atom in the heterocyclic ring; n is an integer from 0 to 8; R.sup.2 is straight, branched cyclic or cyclo-straight alkyl having from one to thirteen carbon atoms, or aralkyl having from seven to thirteen carbon atoms and pharmacologically acceptable acid additional salts thereof have substantially strong and long lasting effects. Therefore the compounds are useful as agents for treating disorders of the cardiovascular system, and are useful, for example, as antihypertensive agents, circulation improvers and antianginal agents.

Abstract: N-substituted 3,4-dihydropyrimidine derivatives of the formula: ##STR1## wherein X.sup.1, X.sup.2 and X.sup.3 are the same or different and are hydrogen, nitro, halogen, cyano, trifluoromethyl, methylthio or lower alkoxy;R.sup.1 is (C.sub.1 -C.sub.13) straight or branched alkoxy, (C.sub.4 -C.sub.12) straight or branched alkenyloxy, (C.sub.5 -C.sub.8) straight or branched alkynyloxy, (C.sub.1 -C.sub.4) straight or branched alkyl, (C.sub.3 -C.sub.6) cycloalkyl,--O--(CH.sub.2).sub.n --A wherein n is 1, 2 or 3, A is cyclopropyl, cyclobutyl, cyclopentyl, or (C.sub.1 -C.sub.3) haloalkyl,--O--(CH.sub.2).sub.m --O--B wherein m is 1, 2, 3 or 4, B is (C.sub.1 -C.sub.3) alkyl, or--O--(CH.sub.2).sub.l --D wherein l is an integer from zero to 8, D is phenyl or substituted phenyl;R.sup.2 is (C.sub.1 -C.sub.12) straight or branched alkyl, (C.sub.4 -C.sub.7) straight or branched alkenyl, --(CH.sub.2).sub.

Abstract: A 3N-substituted 3,4-dihydropyrimidine derivative of the formula: ##STR1## wherein R.sup.1 is methyl or ethyl, R.sup.2 is methyl or ethyl, R is phenyl or substituted phenyl, X is chloro or methyl and pharmaceutically acceptable acid addition salts thereof have substantially the same strong vasodilative and Ca.sup.++ antagonistic effects as nicardipine and therefore are useful as agents for treating disorders of the cardiovascular system, for example, hypotensive agents, agents for amelioration of brain circulation and anti-angina pectoris agents.Processes for producing the above compounds economically and effectively are also disclosed.

Abstract: A novel 1-substituted pyrrolizidine derivative having the formula: ##STR1## (wherein R.sup.1 is hydrogen or a lower alkyl group; R.sup.2 is hydrogen, a lower alkyl or lower alkoxy group, or a halogen; R.sup.3 is hydrogen, a lower alkyl, lower alkoxy or amino group, or a halogen),which can be produced by reacting 1-chlorocarbonyl (or alkoxycarbonyl)pyrrolizidine with a corresponding substituted aniline (or an alkali metal salt thereof). The pyrrolizidine derivative has antiarrhythmic activity.